ATS 2024 Final Program

Click on the session title to view the speakers

SUNDAY • MAY 19

57

P886 A Real-world Study of Patients With Combined Idiopathic Pulmonary Fibrosis and Lung Cancer P887 Minimal Impact of Age =80 on Outcomes in Veterans With Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy P888 The Effect of Frailty on Patient Engagement and Outcomes Using Remote Digital Monitoring in Interstitial Lung Disease P889 Progression of Shadows and Prognosis After Lung Cancer Surgery in Cases With Interstitial Lung Abnormalities P890 Changing Pattern of Clinical Features and Prognosis in Newly Diagnosed Idiopathic Pulmonary Fibrosis P891 Changes in Lung Function and Changes in Patient-reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis (IPF) P892 Diabetes: A Potential Modifiable Risk Factor for Patients With Pulmonary Hypertension and Sarcoidosis P893 Predicting Survival of Patients With Connective Tissue Disease-associated Interstitial Lung Disease Using GAP Model P894 Argentine Patients With Autoimmune Related Interstitial Lung Diseases: First Results From the EPIMAR II Registry P895 Factors Associated With Progression of Interstitial Lung Disease in Patients With Systemic Sclerosis (SSc-ILD) P896 Factors Associated With Symptomatic Interstitial Lung Disease in Patients With Systemic Sclerosis (SSc-ILD) P897 Respiratory-Related Hospitalization and Mechanical Ventilation in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry P898 Development of a Prediction Model for Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Study of the Korea IPF Cohort Registry P899 Prognostic Prediction for Patients With Idiopathic Interstitial Pneumonia: Nationwide Prospective Registry, Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry (NEJ030) P900 Pleuroparenchymal Fibroelastosis: Natural History and Pharmacotherapy in a Tertiary Center Cohort

P901 Combined Pulmonary Fibrosis and Emphysema :highlitings Through Risk Factors for Poor Patient Outcomes P902 Prevalence of Depression in Participants With ILD Versus COPD in a Large Metropolitan Health System P903 Acute Exacerbation of Interstitial Lung Disease Specific Comorbidity Index (AEILD-CI) to Assess the Risk of In-hospital Death: A Prospective Cohort Study P904 Risk Factors at Baseline Evaluation Associated to Initiation of Long Term Oxygen Therapy on Follow Up in Fibrotic Interstitial Lung Disease P905 Evaluating Lung Cancer Risk Factors in Adults With Interstitial Lung Disease P906 Sociodemographic Associations for Early Hospital

Readmission Following Hospital Admission for Interstitial Lung Disease in a Large National Database in the United States

P907 Clinical, Radiological, Physiological, and Histological Impact of Cigarette Smoking on Appalachian Coal Miners P908 Evaluation of Pre-treatment Risk Factors for Development of Trastuzumab Deruxtecan Associated Pneumonitis

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

A48 COPD EXACERBATIONS AND

HOSPITALIZATIONS: DETERMINANTS AND DRIVERS

9:15 a.m. - 4:15 p.m.

San Diego Convention Center Area B (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P141 Multivariable Prediction of Exacerbations in a COPD Population: A Prospective Analysis P142 Modified COPD Exacerbation Recognition Tool for Recognition of the Exacerbations of COPD in China

ATS 2024 Conference Program • San Diego, CA